Lysogene appoints Annette Clancy as Chair of the Board

Experienced pharmaceutical and biotech executive to chair the gene therapy company’s board

PARIS--()--Annette Clancy has been appointed Chair of the Board of Directors, the leading clinical-stage CNS gene therapy company announced today. Ms. Clancy was previously a non-executive member of Lysogene’s board.

Ms. Karen Aiach, Founder and CEO of Lysogene, who has led Lysogene in translating its rAAVrh10 lead product for Sanfilippo from bench to bedside in an unprecedented fashion, stated: “This is an ideal time to have such a senior and dynamic life sciences executive join Lysogene. Annette is a leader in the field and her proven track-record in both business development and R&D will allow us to further advance and expand our gene therapy programmes, enhance our research in the field and further develop our business model”.

Ms. Clancy’s prior roles within the healthcare, life sciences and biotechnology sectors span research and development as well as M&A, partnerships and funding. She will now bring her extensive experience in business development, clinical research, and commercialization of innovative drug therapies to Lysogene. She will be based in the U.K.

Ms. Clancy stated “I am delighted to assume the Chair of the Board at Lysogene at this exciting time when we are expanding and growing the Company to maximise value for shareholders and patients”.

In addition to her role as Chair of Lysogene’s Board of Directors, Ms. Clancy will maintain her role as a non-executive board member of other private and public biotechnology companies. She currently chairs the Board at Genable Technologies Ltd (Ireland) and ObsEva Ltd (Switzerland), and she is a non-executive Director on the board of SOBI Inc. (Sweden).

For more information about LYSOGENE, please visit www.lysogene.com

About Lysogene:

Lysogene is a clinical stage biotechnology company committed to the development and commercialization of innovative therapies for patients affected with orphan disorders and high unmet medical needs. Its lead product is for Sanfilippo syndrome, a neurodegenerative lysosomal storage disorder considered to be a perfect model for gene therapy. LYSOGENE is currently expanding its pipeline to additional diseases with high unmet medical needs, such as GM1. Lysogene was launched in 2009. It completed a Series A financing in May 2014 with leading life sciences investors Sofinnova Partners, BPI Innobio and Novo A/S.

Contacts

Rooney & Associates
Marion Janic, 212-223-4017
mjanic@rooneyco.com

Contacts

Rooney & Associates
Marion Janic, 212-223-4017
mjanic@rooneyco.com